Direct compression of liposomal vitamin C API supplied as a spray-dried phospholipid–mannitol matrix containing 30–50% w/w ascorbic acid requires segregation of the low-bulk-density powder from hygroscopic fillers and protection of the lipid bilayer from excessive compaction shear. Median particle size by laser diffraction is typically 80–180 µm d₅₀, and bulk density ranges from 0.32 g/cm³ to 0.48 g/cm³ under USP 616 Method III. Tablet cores delivering 500–1,000 mg ascorbic acid equivalent are produced with 45–68% w/w liposomal API, 20–35% w/w microcrystalline cellulose, 10–20% w/w dibasic calcium phosphate dihydrate, 2–5% w/w crospovidone, and 0.5–1.5% w/w sodium stearyl fumarate. Blending is performed in a 500 L bin blender at 8–12 RPM for 15–25 min; the lubricant is screened through a 60-mesh sieve before addition. Compression on a 27-station rotary tablet press uses a precompression force of 5–8 kN and a main compression force of 12–22 kN. Tablet hardness is held at 80–140 N, and friability is maintained below 1.0% by USP 1216. Production trials on this equipment class show that main compression forces above 25 kN can collapse the phospholipid bilayer, altering dissolution Q values to below 75% at 45 min in USP 711 Apparatus II at 50 RPM in pH 6.8 phosphate buffer. Content uniformity follows USP 905; batch records require humidity control below 50% RH and bottle sealing with desiccant. Magnesium stearate levels above 1.0% w/w and blend times above 25 min reduce dissolution rate because the hydrophobic film coats the phospholipid surface; sodium stearyl fumarate is therefore used as the preferred lubricant. Published data for this specific formulation configuration is limited outside pharmaceutical development reports; each supplier lot must be revalidated for compression force, bulk density, and dissolution profile before commercial tableting.

Why Hard Capsule Filling of Phospholipid-Coated Ascorbic Acid Stalls Above 45% RH

At relative humidity above 45%, the liposomal API adsorbs surface moisture, increasing particle cohesiveness and causing dosator pin jamming on high-speed capsule machinery. Capsule fill formulations for size 00 or 0 HPMC capsules typically contain 35–55% w/w liposomal vitamin C powder, 30–45% w/w mannitol, 5–10% w/w pregelatinized starch, 2–4% w/w croscarmellose sodium, and 0.5–1.0% w/w fumed silica. The mixture is compacted on a roller compactor at 3–6 MPa and milled through a 1.0 mm screen to produce granules of 150–400 µm; this step reduces segregation and permits filling on dosator-type equipment at 50–70% of rated maximum speed. Dissolution testing follows USP 711 Apparatus II in 900 mL of pH 3.5 citrate buffer with a Q of 80% at 30 min; disintegration is assessed by USP 701. Terminal products are 500 mg and 1,000 mg ascorbic acid equivalent HPMC capsules, closed with desiccant-seal closures. For enteric capsules, the product is additionally tested in 0.1 N hydrochloric acid for 2 h followed by pH 6.8 phosphate buffer, and fill powder moisture is held below 1.5% by USP 921 to prevent HPMC shell deformation during banding. Room dehumidification to 30–45% RH is required; below 25% RH static charging causes segregation and capsule shell powder adhesion, while above 45% RH tackiness increases fill weight coefficient of variation beyond 3.0%.

Because citric acid and sodium bicarbonate react with free water to release heat, effervescent granule systems containing liposomal vitamin C API require a residual water content below 0.5% w/w by Karl Fischer USP 921 and a final water activity below 0.3. A 4 g sachet delivering 1,000 mg ascorbic acid as liposomal API is typically formulated with 25–40% w/w liposomal vitamin C powder, 20–30% w/w anhydrous citric acid, 25–35% w/w sodium bicarbonate, 5–10% w/w sorbitol, and 0.5–1.0% w/w sodium benzoate. The liposomal API is granulated separately in a top-spray fluid-bed processor with anhydrous ethanol containing 5% w/w povidone at an inlet air temperature of 35–50°C, below the phospholipid phase transition range stated in the API certificate of analysis. Dried granules are milled through 500 µm, blended with the effervescent couple in a low-shear ribbon blender at 10–15 RPM for 10 min, and packaged in PET/aluminum/LDPE laminate sachets with nitrogen flushing to maintain headspace oxygen below 2.0%. Loss on drying follows USP 731; reconstitution in 200 mL water at 25°C yields a maximum dispersion time of 90 s. Terminal products include 1,000 mg ascorbic acid equivalent effervescent granules and low-sodium variants for adult immune support. Because the acid-base couple creates a pH swing from 3.0 to 5.5 during dissolution, separate granulation or pH-neutralization with potassium bicarbonate is required to maintain encapsulation efficiency above 80% by ultracentrifugation assay. Potassium bicarbonate replacement for sodium bicarbonate in low-sodium formulations changes gas volume and dissolution rate; each variant must be revalidated under USP 711 rather than relying on the sodium form as a direct substitute.

When Lyophilized Injectable Liposomal Vitamin C Retains Water Above 3% After Secondary Drying

For lyophilized injectable formulations, the pre-lyophilization liposome dispersion is prepared with 5–15 mg/mL ascorbic acid as liposomal API, 5–10% w/v trehalose or sucrose as cryoprotectant, and a phospholipid-to-ascorbic acid weight ratio of 0.5:1 to 1.2:1. The dispersion is homogenized in a high-pressure homogenizer equipped with a diamond interaction chamber at 10,000–20,000 psi for 3–5 discrete passes, then filtered through a 0.2 µm sterilizing-grade membrane into sterile Type I borosilicate vials. Freezing is performed on pre-cooled shelves at −40°C; primary drying is run at −20°C and 50–100 mTorr; secondary drying is ramped to 25°C and 20 mTorr for a total cycle time of 48–72 h. The resulting lyophilized cake typically contains 15–40% w/w API, 30–60% w/w cryoprotectant, and 20–40% w/w phospholipids, with Karl Fischer moisture below 3.0% w/w by USP 921. Cake fracture and slow reconstitution occur when the cryoprotectant ratio falls below 5% w/v or when secondary drying exceeds 30°C, both of which damage the lipid bilayer. Freeze-dry microscopy batches with 5% w/v trehalose show incipient collapse at product temperatures above −28°C; shelf fluid temperature and product thermocouple readings must therefore remain below this threshold during primary drying. The powder is reconstituted with Sterile Water for Injection to a concentration of 25–50 mg/mL ascorbic acid equivalent. Injectable quality control includes bacterial endotoxins by USP 85, subvisible particulate matter by USP 788, and liposome mean particle size by dynamic light scattering according to ISO 22412:2017. Terminal steam sterilization at 121°C for 15 min is not viable for this product class due to particle aggregation and phospholipid hydrolysis; aseptic processing under current FDA liposome guidance and 21 CFR 211 is required.

Sterile-Filterable Liposome Dispersion Homogenization Pressure and Temperature Limits

During high-pressure homogenization of ready-to-use injectable liposomal vitamin C, the interaction chamber outlet temperature must remain below 45°C to prevent phase transition-induced bilayer fusion. Aseptic dispersions are prepared at 5–30 mg/mL ascorbic acid equivalent with total lipid content of 10–40 mg/mL and cholesterol at 20–40 mol% of total phospholipid. The vitamin C-to-lipid weight ratio is maintained between 0.25:1 and 0.75:1; ratios above 0.75:1 shift the z-average hydrodynamic diameter above 200 nm and reduce sterile filter flux on 0.2 µm polyethersulfone membranes. Homogenization is performed at 10,000–30,000 psi for 3–5 passes, followed by extrusion through 0.2 µm polycarbonate track-etched membranes to narrow the liposome size distribution. The dispersion is adjusted to pH 5.5–6.5 with dilute sodium hydroxide because ascorbate oxidation in the presence of phospholipid bilayers is slower near pH 6.5 than at acidic pH below 5.0; isotonicity is achieved with 5% w/v dextrose. The product is filled under nitrogen into Type I borosilicate vials and stoppered with a nitrogen overlay; glass-lined mixing vessels are used because trace iron catalyzes phospholipid oxidation. In-process controls include z-average particle size and polydispersity index by ISO 22412:2017, pH, osmolality per USP 785, and filter integrity by bubble point test. The terminal dosage form is a 10 mL single-use intravenous infusion concentrate to be diluted in 0.9% sodium chloride injection or 5% dextrose injection. Sterile filtration is mandatory because terminal autoclaving at 121°C for 15 min causes irreversible particle coalescence and phospholipid hydrolysis; environmental control follows ISO 14644-1 Class 5 filling zones with 21 CFR 211.113 contamination control, and sterility testing follows USP 71.

Oral powder-for-suspension systems that require a low-sodium, sugar-free vehicle and dose flexibility are processed by fluid-bed granulation rather than aqueous wet granulation because residual water above 0.8% w/w by USP 921 reduces encapsulation efficiency. A unit dose sachet delivering 250 mg or 500 mg ascorbic acid equivalent typically uses 20–45% w/w liposomal vitamin C API, 40–60% w/w mannitol, 3–6% w/w sodium starch glycolate, 0.5–1.5% w/w xanthan gum, and 0.2–0.8% w/w colloidal silicon dioxide. Granulation is performed in a fluid-bed processor with a 2% w/w ethanolic povidone solution sprayed at an inlet air temperature of 40–60°C; the spray rate is held at 8–12 g/min per kg of dry material to prevent overwetting and lipid bilayer rupture. Granules are dried to 0.5–1.0% w/w moisture, passed through a 710 µm screen, and filled into polyester/aluminum foil/polyethylene sachets under nitrogen. Residual ethanol is controlled under ICH Q3C Class 3 limits. Disintegration and dispersion of the reconstituted suspension are tested by USP 711 Apparatus II at 25 RPM in 500 mL pH 6.8 phosphate buffer; content uniformity follows USP 905. Terminal products include single-dose dry syrup sachets for adults with dysphagia and 250 mg ascorbic acid equivalent pediatric formulations. Xanthan gum levels above 1.5% w/w should be avoided because high viscosity impedes dissolution and masks release kinetics during QC testing. If an in-use reconstituted suspension hold time above 30 min is claimed, the period must be justified by validated assay and encapsulation efficiency data under ICH Q1A conditions; otherwise, administration should occur immediately after reconstitution to limit phospholipid hydrolysis and ascorbate oxidation.